Skip to main content

Advertisement

SpringerLink
Log in

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We previously reported progression-free survival (PFS) results on a phase II trial of weekly paclitaxel, trastuzumab, and pertuzumab in patients with human epidermal growth factor receptor 2(HER2)–positive metastatic breast cancer (MBC) treated in the first- and second-line setting. Here, we report results for overall survival (OS) and updated PFS after an additional year of follow-up. Patients with HER2-positive MBC with 0–1 prior treatment were eligible. Treatment consisted of paclitaxel (80 mg/m2) weekly, and trastuzumab (loading dose 8 mg/kg → 6 mg/kg) and pertuzumab (loading dose 840 mg → 420 mg) every 3 weeks, all given intravenously. Primary endpoint was 6-month PFS. Secondary endpoints included median PFS, 6-month and median OS. Evaluable patients received at least one full dose of treatment. From January 2011 to December 2013, 69 patients were enrolled: 51 (74 %) and 18 (26 %) treated in first- and second-line metastatic settings, respectively. As of July 1, 2015, the median follow-up was 33 months (range 3–49 months; 67 patients were evaluable for efficacy). The median OS was 44 months (95 % CI 37.5–NR) overall and 44 months (95 % CI 38.3–NR) and 37.5 months (95 % CI 30.3–NR) for patients with 0 and 1 prior metastatic treatment, respectively; 6-month OS was 98 % (95 % CI 90-1). The 6-month PFS was 86 % (95 % CI 75–93) overall and 89 % (95 % CI 76–95) and 78 % (95 % CI 51–91) for patients with 0 and 1 prior therapy, respectively; and median PFS was 21.4 months (95 % CI 14.1–NR) overall and 25.7 months (95 % CI 14.1–NR) and 16.9 months (95 % CI 8.5–NR) for patients with 0–1 prior treatment, respectively. Treatment was well tolerated. Updated analysis demonstrates that weekly paclitaxel, when added to trastuzumab and pertuzumab, is associated with a favorable OS and PFS and offers an alternative to docetaxel-based therapy. http://www.ClinicalTrials.gov NCT0127604

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 235(4785):177–182

    Article  CAS  Google Scholar 

  2. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L et al (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16(4):1340–1349

    CAS  PubMed  Google Scholar 

  3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M et al (2001) Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 344(11):783–792

    Article  CAS  PubMed  Google Scholar 

  4. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119

    Article  CAS  PubMed  Google Scholar 

  5. Hudis CA (2007) Trastuzumab— Mechanism of Action and Use in Clinical Practice. N Engl J Med 357(1):39–51

    Article  CAS  PubMed  Google Scholar 

  6. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5(4):317–328

    Article  CAS  PubMed  Google Scholar 

  7. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463–475

    Article  CAS  PubMed  Google Scholar 

  8. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K et al (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2(2):127–137

    Article  CAS  PubMed  Google Scholar 

  9. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69(24):9330–9336

    Article  CAS  PubMed  Google Scholar 

  10. Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461–471

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734

    Article  CAS  PubMed  Google Scholar 

  12. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dang C, Iyengar N, Datko F, D’Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M et al (2015) Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33(5):442–447

    Article  CAS  PubMed  Google Scholar 

  14. Gradishar WJA, Benjamin O (2015) Balassanian, Ron Blair et al.: Breast Cancer Version 2.2015. J Natl Compr Canc Netw 13(4):448–475

    CAS  PubMed  Google Scholar 

  15. Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA et al (2016) Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. The Oncologist 21(4):418–424

    Article  PubMed  Google Scholar 

  16. Andersson M, López-Vega JM, Petit T, Zamagni C, Donica M, Kamber J, Perez EA (2015) The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis. J Clin Oncol 33(15):586 2015 ASCO Annual Meeting

    Google Scholar 

  17. Perez EA, Lopez-Vega JM, Mastro LD, Petit T, Mitchell L, Pelizon CH, Andersson M (2012) A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET). J Clin Oncol 30(15):TPS653 2012 ASCO Annual Meeting

    Google Scholar 

  18. Andersson M, Lopez-Vega JM, Petit T, Zamagni C, Freudensprung U, Robb S, Restuccia E, Perez EA (2014) 361PDINTERIM SAFETY AND EFFICACY OF PERTUZUMAB, TRASTUZUMAB AND VINORELBINE FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (PTS) WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC). Annals of Oncology 25(4):iv120–iv120

    Google Scholar 

  19. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32

    Article  CAS  PubMed  Google Scholar 

  20. Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, Pazdur R, Cortazar P (2014) First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 20(21):5359–5364

    Article  CAS  Google Scholar 

  21. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 24(9):2278–2284

    Article  CAS  Google Scholar 

  22. Von Minckwitz G, Baselga J, Bradbury I, de Azambuja E, Scullion M, Ross G, Saini K, Piccart-Gebhart M (2011) Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4–11/BO25126/TOC4939 g). Cancer Research 71(24 Supplement):OT1-02–04

    Google Scholar 

  23. A Study of Kadcyla (TrastuzumabEmtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer. http://clinicaltrials.gov/ct2/show/NCT01966471

  24. Ellis PA, Barrios CH, Eiermann W, Toi M, Im Y-H, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA et al (2015) Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. J Clin Oncol 33(15):507

    Google Scholar 

Download references

Acknowledgments

We thank all the study investigators and their clinical teams for their contribution to this study, and the patients for agreeing to participate.

Funding

This work was supported by Roche-Genentech. No grant applied.

Author information

Authors and Affiliations

  1. Breast Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY, 10065, USA

    L. M. Smyth, N. M. Iyengar, M. F. Chen, S. M. Popper, J. C. Singh, S. Chandarlapaty, S. M. Sugarman, E. A. Comen, P. R. Drullinsky, T. A. Traina, T. Troso-Sandoval, J. Baselga, L. Norton, C. A. Hudis & C. T. Dang

  2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA

    S. Patil

  3. NewYork-Presbyterian/Lawrence Hospital, New York, USA

    C. Wasserheit-Lieblich

  4. CLION, Salvador, Brazil

    D. F. Argolo

Authors
  1. L. M. Smyth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. M. Iyengar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. F. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. M. Popper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Patil
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Wasserheit-Lieblich
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. F. Argolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. C. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Chandarlapaty
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. M. Sugarman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E. A. Comen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P. R. Drullinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T. A. Traina
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. T. Troso-Sandoval
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J. Baselga
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. L. Norton
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C. A. Hudis
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. C. T. Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. M. Smyth.

Ethics declarations

Conflict of interest disclosures

LMS, NMI, MFC, SMP, SP, CWL, DFA, JCS, SC, SMS, EAC, PD, TTS, JB, LN: no COI.CAH: Consulting- Genentech, CTD: Research funding-Genentech/Roche. TAT: Advisory–Genentech.DFA: Travel- Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Smyth, L.M., Iyengar, N.M., Chen, M.F. et al. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat 158, 91–97 (2016). https://doi.org/10.1007/s10549-016-3851-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-016-3851-7

Keywords

Search

Navigation